{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:19:07Z","timestamp":1793837947045,"version":"4.6.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MicroRNAs (miRNAs), small and highly conserved non-coding RNA molecules, have emerged as promising molecular biomarkers due to their regulatory roles in gene expression and stability in blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used measurements of 64 plasma miRNAs from 145 participants in the Alzheimer\u2019s disease Neuroimaging Initiative cohort, including 74 probable AD patients and 71 cognitively normal (CN) older adults. We performed principal component analysis (PCA) with factor rotation for dimension reduction to identify AD-associated principal components (PCs) and their key miRNAs with factor loadings higher than 0.8. We investigated their association with amyloid\/tau\/neurodegeneration (A\/T\/N) biomarkers and cognition. After identifying the candidate target genes of key miRNAs, we performed pathway enrichment analysis. We conducted mediation analyses to assess the effect of the associations between miRNAs and A\/T\/N biomarkers on AD diagnosis and cognition. Finally, we used a machine learning approach to evaluate the performance of key miRNAs for AD classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCA identified one PC as significantly associated with AD. The PC was also significantly associated with CSF p-tau levels, hippocampal volume, and cognition. Two key miRNAs (miR-423-5p and miR-92a-3p) in the PC were associated with AD. Lower levels of miR-423-5p and miR-92a-3p were associated with reduced hippocampal volume and worse cognition, and lower levels of miR-423-5p were associated with higher brain amyloid deposition. Pathway enrichment analysis identified several significant biological processes, including memory, protein phosphorylation, and the phosphatidylinositol-3-phosphate biosynthetic process. Mediation analysis revealed that miR-423-5p, but not miR-92a-3p, had indirect effects on AD diagnosis and memory performance through brain amyloid deposition and brain atrophy. Machine learning analysis demonstrated that incorporating two key miRNAs improved the performance of demographic information for AD classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma miR-423-5p and miR-92a-3p are implicated in AD pathology and cognitive decline, providing insights into their roles in disease mechanisms. This study suggests the potential of these miRNAs as blood-based molecular biomarkers for AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2025.1637368","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:31:07Z","timestamp":1753162267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["miR-423-5p and miR-92a-3p in Alzheimer\u2019s disease: relationship with pathology and cognition"],"prefix":"10.3389","volume":"17","author":[{"given":"Sang-Won","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Pyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Bice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangsik","family":"Nho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref1","author":"Abdalla","year":"2011"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","article-title":"Clinical Core of the Alzheimer's disease neuroimaging Initiative: progress and plans","volume":"6","author":"Aisen","year":"2010","journal-title":"Alzheimers Dement."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jalz.2015.05.005","article-title":"Alzheimer\u2019s disease neuroimaging initiative 2 clinical core: progress and plans","volume":"11","author":"Aisen","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41467-020-14959-w","article-title":"Sex and APOE \u03b54 genotype modify the Alzheimer\u2019s disease serum metabolome","volume":"11","author":"Arnold","year":"2020","journal-title":"Nat. Commun."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1228927","DOI":"10.3389\/fnins.2023.1228927","article-title":"Common microRNA regulated pathways in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"17","author":"Awuson-David","year":"2023","journal-title":"Front. Neurosci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","article-title":"Micrornas: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Stat Methodol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1007\/s12035-023-03446-0","article-title":"Discerning the prospects of miRNAs as a multi-target therapeutic and diagnostic for Alzheimer\u2019s disease","volume":"60","author":"Bhatnagar","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1039\/c2mb25434d","article-title":"Studying the differential co-expression of microRNAs reveals significant role of white matter in early Alzheimer's progression","volume":"9","author":"Bhattacharyya","year":"2013","journal-title":"Mol. BioSyst."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1\u201342) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/01621459.1961.10482090","article-title":"Multiple comparisons among means","volume":"56","author":"Dunn","year":"1961","journal-title":"J. Am. Stat. Assoc."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1037\/1082-989X.4.3.272","article-title":"Evaluating the use of exploratory factor analysis in psychological research","volume":"4","author":"Fabrigar","year":"1999","journal-title":"Psychol. Methods"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e12251","DOI":"10.1002\/dad2.12251","article-title":"Plasma microRNA vary in association with the progression of Alzheimer's disease","volume":"14","author":"Gu\u00e9vremont","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/03637750903310360","article-title":"Beyond baron and Kenny: statistical mediation analysis in the new millennium","volume":"76","author":"Hayes","year":"2009","journal-title":"Commun. Monogr."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jalz.2010.03.004","article-title":"Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative","volume":"6","author":"Jack","year":"2010","journal-title":"Alzheimers Dement."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","article-title":"The Alzheimer's disease neuroimaging Initiative positron emission tomography core","volume":"6","author":"Jagust","year":"2010","journal-title":"Alzheimers Dement."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","article-title":"The Alzheimer's disease neuroimaging initiative 2 PET core: 2015","volume":"11","author":"Jagust","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref27","volume-title":"Principal component analysis for special types of data","author":"Jolliffe","year":"2002"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"20150202","DOI":"10.1098\/rsta.2015.0202","article-title":"Principal component analysis: a review and recent developments","volume":"374","author":"Jolliffe","year":"2016","journal-title":"Philos. Trans. A. Math. Phys. Eng. Sci."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jalz.2015.05.003","article-title":"The Alzheimer\u2019s disease neuroimaging initiative 2 biomarker core: a review of progress and plans","volume":"11","author":"Kang","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fneur.2020.00288","article-title":"The regulation of microRNAs in Alzheimer's disease","volume":"11","author":"Kou","year":"2020","journal-title":"Front. Neurol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ymthe.2016.10.010","article-title":"Correcting miR92a-vGAT-mediated GABAergic dysfunctions rescues human tau-induced anxiety in mice","volume":"25","author":"Li","year":"2017","journal-title":"Mol. Ther."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/bib\/bbw113","article-title":"A review on machine learning principles for multi-view biological data integration","volume":"19","author":"Li","year":"2018","journal-title":"Brief. Bioinform."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/now129","article-title":"miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas","volume":"19","author":"Li","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"15353","DOI":"10.18632\/aging.203094","article-title":"Alisol A 24-acetate protects against brain microvascular endothelial cells injury through inhibiting miR-92a-3p\/tight junctions axis","volume":"13","author":"Lu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-160835","article-title":"MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer\u2019s disease","volume":"55","author":"Lusardi","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1002\/alz.14197","article-title":"Blood-derived microRNAs are related to cognitive domains in the general population","volume":"20","author":"Melas","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/bib\/bbv108","article-title":"Dimension reduction techniques for the integrative analysis of multi-omics data","volume":"17","author":"Meng","year":"2016","journal-title":"Brief. Bioinform."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/genes9040174","article-title":"The role of microRNAs in Alzheimer\u2019s disease and their therapeutic potentials","volume":"9","author":"Miya Shaik","year":"2018","journal-title":"Genes (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcmm.12236","article-title":"Methodological challenges in utilizing mi RNA s as circulating biomarkers","volume":"18","author":"Moldovan","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/ncomms3250","article-title":"Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system","volume":"4","author":"Morel","year":"2013","journal-title":"Nat. Commun."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2412-2412-a","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The clinical dementia rating (CDR) current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/wnl.39.9.1159","article-title":"The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1745-9125.1998.tb01268.x","article-title":"Using the correct statistical test for the equality of regression coefficients","volume":"36","author":"Paternoster","year":"1998","journal-title":"Criminology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"15589","DOI":"10.1038\/s41598-022-19862-6","article-title":"Plasma microRNAs as potential biomarkers in early Alzheimer disease expression","volume":"12","author":"Pe\u00f1a-Bautista","year":"2022","journal-title":"Sci. Rep."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.csda.2004.06.015","article-title":"How many principal components? Stopping rules for determining the number of non-trivial axes revisited","volume":"49","author":"Peres-Neto","year":"2005","journal-title":"Comput. Stat. Data Anal."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's disease neuroimaging Initiative (ADNI) clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1127163","DOI":"10.3389\/fnmol.2023.1127163","article-title":"Identification of miRNAs regulating MAPT expression and their analysis in plasma of patients with dementia","volume":"16","author":"Piscopo","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref52","volume-title":"The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation","author":"Reitan","year":"1985"},{"key":"ref53","author":"Rey","year":"1983"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nbt0308-303","article-title":"What is principal component analysis?","volume":"26","author":"Ringn\u00e9r","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e12028","DOI":"10.1002\/jev2.12028","article-title":"Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: an exploratory study","volume":"10","author":"Sandau","year":"","journal-title":"J. Extracell. Vesicles"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"864022","DOI":"10.3389\/fcell.2022.864022","article-title":"Differential effects of APOE genotype on MicroRNA cargo of cerebrospinal fluid extracellular vesicles in females with Alzheimer\u2019s disease compared to males","volume":"10","author":"Sandau","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41598-024-52681-5","article-title":"Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers","volume":"14","author":"Sandau","year":"2024","journal-title":"Sci. Rep."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JAD-200396","article-title":"Performance of validated microRNA biomarkers for Alzheimer\u2019s disease in mild cognitive impairment","volume":"78","author":"Sandau","year":"","journal-title":"J Alzheimer's Dis"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1317577","DOI":"10.1080\/20013078.2017.1317577","article-title":"Analysis of extracellular RNA in cerebrospinal fluid","volume":"6","author":"Saugstad","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014recommendations from the global CEO Initiative on Alzheimer\u2019s disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref61","author":"Scientific","year":"2017"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0501-4","article-title":"Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer\u2019s disease","volume":"11","author":"Siedlecki-Wullich","year":"2019","journal-title":"Alzheimer's Res Ther"},{"key":"ref63","author":"TaqMan","year":"2011"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.18637\/jss.v059.i05","article-title":"Mediation: R package for causal mediation analysis","volume":"59","author":"Tingley","year":"2014","journal-title":"J. Stat. Softw."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref66","first-page":"201","volume-title":"STREAMLINE: a simple, transparent, end-to-end automated machine learning pipeline facilitating data analysis and algorithm comparison, Genetic Programming Theory and Practice XIX","author":"Urbanowicz","year":"2023"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00401-010-0756-0","article-title":"Patterns of microRNA expression in normal and early Alzheimer\u2019s disease human temporal cortex: white matter versus gray matter","volume":"121","author":"Wang","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fgene.2019.00153","article-title":"Micrornas in Alzheimer\u2019s disease","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Genet."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","article-title":"The microRNA spectrum in 12 body fluids","volume":"56","author":"Weber","year":"2010","journal-title":"Clin. Chem."},{"key":"ref70","volume-title":"WMS-R: Wechsler memory scale-revised","author":"Wechsler","year":"1987"},{"key":"ref71","volume-title":"Wechsler adult intelligence scale-revised","author":"Wechsler","year":"1981"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","article-title":"A current view on tau protein phosphorylation in Alzheimer's disease","volume":"69","author":"Wegmann","year":"2021","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","article-title":"The Alzheimer's disease neuroimaging Initiative 3: continued innovation for clinical trial improvement","volume":"13","author":"Weiner","year":"2017","journal-title":"Alzheimers Dement."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JAD-180539","article-title":"Validation of microRNA biomarkers for Alzheimer\u2019s disease in human cerebrospinal fluid","volume":"67","author":"Wiedrick","year":"2019","journal-title":"J Alzheimer's Dis"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","article-title":"Many roads to maturity: microRNA biogenesis pathways and their regulation","volume":"11","author":"Winter","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"D146","DOI":"10.1093\/nar\/gku1104","article-title":"miRDB: an online resource for microRNA target prediction and functional annotations","volume":"43","author":"Wong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/alz.12752","article-title":"Genome-wide profiling of circulatory microRNAs associated with cognition and dementia","volume":"19","author":"Yaqub","year":"2023","journal-title":"Alzheimers Dement."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1637368\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:31:09Z","timestamp":1753162269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1637368\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":77,"alternative-id":["10.3389\/fnagi.2025.1637368"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2025.1637368","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1637368"}}